Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment